The North American plant-based biologics market is expected to reach $87.3 million by 2026.

 

Plant-based biologics (also known as plant-made biologics or PMB) are Schedule D (biologic) drugs produced by plant molecular farming. Due to restricted scalability and greater costs, current production platforms such as mammalian cell culture cannot meet the rapidly increasing worldwide demand for pharmaceuticals. Plants have several advantages, including the capacity to modify eukaryotic proteins and the possibility for low cost and high scalability. As a result, some plants, such as carrot, tobacco, Alfalfa, and others, are highly chosen for biologic production. Expression vectors, innovative vaccination candidates, plant host systems, and glycol-engineering are among the areas where researchers are concentrating their efforts.

By 2026, the global market for plant-based biologics is expected to reach $164.2 million, up from $102.0 million in 2018, with a high CAGR of 6.1 percent. During the anticipated period, the European plant-based biologics market is expected to rise at a robust CAGR of 8.1 percent, creating $51.5 million in revenue. The asia-Pacific market is predicted to grow as a result of strategic alliances and technical advancements.

The global plant-based biologics market has been propelled in recent years by a significant increase in global demand for biologics, mostly due to the rise in cases of chronic diseases such as diabetes, heart disease, Alzheimer's disease, and others.

One of the important aspects driving the global market for plant-based biologics is the elimination of potential contamination from adventitious agents, which is one of the key drivers driving the rise of plant-based biologics. Furthermore, plant-based biologics have several advantages, including low cost and the capacity to manufacture unique and complex compounds. Furthermore, several established players are employing tobacco, moss, duckweed, alfalfa, and other plants to generate plant-derived biologics. Recent research in plant-based biologics, such as plant expression vector creation, downstream processing, and glycol-engineering is also expected to drive the market for global plant-based biologics.

During the forecast period, substitutes such as mammalian biopharmaceuticals are expected to hinder the growth of the plant-based biologics market. Factors such as adverse reactions to pharmaceuticals made from genetically modified plants are also expected to stymie the expansion of the plant-based biologics sector.

Many major market players are emphasizing the growing promise of plant-based biologics. Novel transient expression vectors, which are more advanced than typical plant-derived biologics, have recently been produced. These biologics enable the development of cutting-edge vaccines and medicines to combat bioterrorism and possible pandemics. Furthermore, these plant-based biologics have advantages such as cheaper costs, great scalability, and the potential to modify eukaryotic proteins. Furthermore, these plant-derived biologics have the potential to act as biocontrol agents for food-borne diseases. As a result, the aforementioned variables are expected to generate attractive chances for plant-based biologics' growth.

Plant-based biologics market share in Europe is expected to grow at an annual rate of 8.1 percent, generating $51.5 million in sales by 2026. Growing technical advancements, substantial expenditures in R&D departments, and state-of-the-art novel technique are some of the factors expected to enhance demand for plant-based biologics products. Companies are also focusing more on strategic partnerships to build manufacturing facilities and plant-based expression technology in countries like Spain, the Czech Republic, and Germany, which is expected to boost the growth of the Asian plant-based biologics market.